Skip to main content
Fig. 7 | Cardiovascular Diabetology

Fig. 7

From: The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin

Fig. 7

Cardiac function studies in mice treated with saline solution (Sham), EMPA 10 mg/kg/day, DOXO 2.17 mg/kg/day or EMPA plus DOXO (n = 6 for each group). A Radial and Longitudinal Strain are expressed as Pk (%). B representative radial and longitudinal strain images for each group. (two-way ANOVA with a Bonferroni post hoc test). Values are expressed ± SD. *** P < 0.001; **P < 0.01; * P < 0.05; ns: not significant

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840